Features of the drug Nimefast - detailed instructions for use

Features and characteristics

The active ingredient of the drug is nimesulide 100 mg. Belongs to non-steroidal anti-inflammatory drugs.

The main effect is to reduce temperature, relieve inflammation, eliminate pain, which is achieved by suppressing the formation of free radicals and the production of prostanoids.

The drug is well absorbed, the maximum accumulation in the inflamed area is 46%, in the joint fluid 42%. The substance is eliminated through the kidneys and liver.

Indications for use of Nymefast tablets

Let's determine what Nymefast tablets help with:

1. Pathologies of the musculoskeletal system, accompanied by pain and inflammation during degenerative-dystrophic changes. These are all types of arthritis, tendinitis, bursitis, myositis, etc.;
2. Toothache and headache;
3. Injuries and wounds;
4. Myalgia, neuralgia, arthralgia;
5. Algodysmenorrhea (pain during menstruation, which worsens general well-being);
6. Reducing temperature during febrile conditions, acute respiratory viral infections and influenza.

Nymefast took three tablets, what should I do?

With long-term use it does not accumulate. Nimesulide is extensively metabolized in the liver by various routes, including cytochrome P450 (CYP) 2C9 isoenzymes. Therefore, there is a potential for drug interactions when coadministering drugs that are metabolized by CYP2C9. Indications for use

• Treatment of acute pain associated with injuries of the musculoskeletal system, injuries and wounds of soft tissues, inflammatory diseases of the musculoskeletal system (arthritis, bursitis, myositis).
• Symptomatic treatment of pain due to osteoarthritis.
• Primary dysmenorrhea.

The decision to prescribe Nymefast should be based on an assessment of the patient's individual risk factors.

httpv://www.youtube.com/watch?v=embed/xcAfXhSJQMg

^ Method of administration and dosage Take orally after meals.

And the only way to avoid this is to remove or maintain the tooth in normal condition - this is Nimesulide, or Nimegesik, or Nimefast. I like Nymefast the most, since it is almost tasteless, you can take it by simply chewing the tablet until completely dissolved, or dissolve it in a glass of water, fifty or one hundred grams. The tablet dissolves perfectly in water, turning it yellowish.

The liquid medicine has absolutely no taste and is easy to drink. Relief comes very quickly and the inflammation goes away. I take this medicine for no more than five days, or even less. I have to do this every six months, or 8 months, or remove the tooth, I prefer to delay the removal.

There are contraindications, so a visit to the doctor is a must. For dental pain, I will definitely recommend this medicine. It helps great. Be healthy and try not to get sick. NIMEFAST Name of the drug: Trade name: Nimefast International nonproprietary name: Nimesulide General characteristics: Nimesulide, 100 mg. The tablets are almost white with a yellowish tint, round, biconvex, with a smooth surface. Composition of the medicinal product: Each tablet contains the active ingredient: Nimesulide 100 mg; excipients: microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate, povidone, lactose. ^ Dosage form: tablets. ATX code: M01AX17. Pharmacotherapeutic group Other non-steroidal anti-inflammatory and antirheumatic drugs. Nimesulide. ^ Pharmacological properties Pharmacodynamics Nimefast is a non-steroidal anti-inflammatory drug (NSAID) from the sulfonanilide class. Has anti-inflammatory, analgesic and antipyretic effects.

What are the contraindications?

• Individual sensitivity to the drug or other non-steroidal drugs, including aspirin;
• Erosion and ulcer of the stomach and duodenum in the acute period;
• History of gastric bleeding;
• Bleeding disorders;
• Pathologies of the kidneys and liver;
• Pregnancy and breastfeeding period;
• Children under 12 years old;
• Enterocolitis;
• Cirrhosis of the liver;
• Alcohol and drug addictions;
• Blood coagulation pathologies;
• Heart defects and heart failure;
• This drug should not be prescribed concomitantly with other non-steroidal anti-inflammatory drugs.

The drug is prescribed with caution for high blood pressure and type II diabetes mellitus.

Nimefast 100mg tablets instructions for use

History of gastrointestinal tract; ■ history of cerebrovascular hemorrhages; ■ severe blood coagulation disorders (pathology of the components of the hemostasis system, for example: coagulopathy, thrombocytopathy, vasopathy, combined hemostasiopathy); ■ severe renal failure (creatinine clearance less than 30 ml/min); ■ severe heart failure; ■ liver dysfunction, liver failure; ■ alcoholism, drug dependence; ■ history of hepatotoxic reactions to nimesulide, simultaneous administration with other hepatotoxic drugs; ■ increased body temperature and/or flu-like symptoms Pregnancy and lactation Not recommended for use during pregnancy.

Nimefast: instructions for use and dosage regimen

The drug is taken orally. To reduce the likelihood of side effects, it is necessary to take the tablets after meals and in the minimum effective dosage.

Before taking, the tablet must be dissolved in water (50-100ml) or chewed completely. The prepared solution cannot be stored.

For adults, the dosage of the drug per day is 100 mg twice a day. Children 12-18 years old – 100 mg per day; if the child’s weight exceeds 40 kg, then the daily dose can be increased by 100 mg.

Instructions for use of Nimefast determine the duration of taking the drug - no more than two weeks.

Patients with renal failure (creatinine clearance from 30 to 80 ml/min) and the elderly do not need to reduce the dosage.

What side effects may occur when taking Nymefast?

• CNS. Dizziness, headache, drowsiness or insomnia, anxiety and depression;
• Organs of vision. Decreased visual acuity;
• Respiratory system. Shortness of breath, bronchospasm;
• Gastrointestinal tract. Dyspeptic disorders (heartburn, nausea, vomiting), stool disorders (diarrhea, constipation), epigastric pain, ulcerative lesions of the gastric mucosa, oral cavity and duodenum, gastric bleeding, liver dysfunction, congestion in the gallbladder, acute hepatitis ;
• Circulatory system. Anemia (decreased hemoglobin level), thrombocytopenia (decreased platelet count), leukopenia (decrease in white blood cell count), increased liver tests (ALT and AST);
• Metabolism. Increased potassium;
• Urinary system. Swelling of tissues and organs, fluid retention, decreased amount of urine excreted, nephritis;
• Heart and blood vessels. Rhythm disturbances, rapid heartbeat, increased blood pressure;
• Allergic manifestations. Rash, dermatitis, erythema, urticaria, rarely - anaphylactic shock and angioedema.

special instructions

Nymefast is not recommended for women who are trying to get pregnant, as the drug reduces fertility. As a result of the fact that the active substance - nimesulide - suppresses the connection of prostanoids, pulmonary hypertension, premature closure of the ductus arteriosus, oliguria, the likelihood of bleeding, weak labor, and edema may develop.

The development of renal failure occurred in the children of those women who took this anti-inflammatory drug in the last stages of pregnancy.

Elderly patients are much more likely to be affected by side effects from taking anti-inflammatory drugs, so Nymefast to this group of patients should be prescribed in minimal doses and under strict monitoring of blood counts, kidney function, liver and heart function.

The likelihood of side effects can also be reduced by discontinuing the drug when a positive effect from treatment is achieved.

You cannot use Nymefast and other painkillers, even from a different pharmacological group, as the likelihood of stroke, heart attack and thrombopulmonary embolism increases.

Medicine knows cases of significant liver damage even as a result of short-term use of the drug, so patients who experienced deterioration in liver parameters on Nymefast, nausea, vomiting, dark urine, severe abdominal pain, must urgently discontinue the drug and never prescribe it again.

If a person’s body temperature rises during therapy with this drug, it is also necessary to interrupt treatment.

Nymefast should be taken with extreme caution in people undergoing anticoagulant therapy.

The drug contains lactose and is therefore not recommended for persons with genetic galactose intolerance.

You should not drink alcoholic beverages during anti-inflammatory drug therapy.

Nymefast tablets 100 mg No. 10x2

Name

Nimefast tablet 100 mg in container pack No. 10x2

Description

Light yellow round, biconvex tablets.

Main active ingredient

Nimesulide

Release form

Pills

Dosage

100mg

Indications for use

Treatment of acute pain; Primary dysmenorrhea. Nimesulide can only be prescribed as a second-line treatment. The decision to prescribe nimesulide should be based on an overall risk assessment for each patient.

Directions for use and doses

In order to minimize unwanted side effects, the minimum effective dose should be taken for the shortest duration of treatment. The maximum duration of treatment with nimesulide is 15 days. Adult patients: 1 tablet (100 mg nimesulide) twice a day after meals. Elderly patients When treating elderly patients, there is no need to reduce the daily dose. Children and adolescents Children (under 12 years of age): for this category of patients, the use of nimesulide-containing medications is contraindicated. Adolescents (12 to 18 years): Based on the pharmacokinetic profile in adults and the pharmacodynamic characteristics of nimesulide, no dose adjustment is necessary in adolescents. Patients with impaired renal function Based on pharmacokinetic data, there is no need for dose adjustment in patients with mild to moderate forms of renal failure (creatinine clearance 30-80 ml/min), while in patients with severe renal failure (creatinine clearance

Use during pregnancy and lactation

Not recommended for use during pregnancy. The use of nimesulide may impair female fertility and is not recommended for women planning pregnancy, having difficulty becoming pregnant, or undergoing examination for infertility. Like other NSAIDs that are known to inhibit prostaglandin synthesis, nimesulide may cause premature closure of the ductus arteriosus, pulmonary hypertension, oliguria, oligoamnion, increased risk of bleeding, weakness of labor and the development of peripheral edema. There have been isolated cases of renal failure in children of women taking nimesulide in late pregnancy. Use during lactation Passes into breast milk, therefore, its use during lactation is not recommended.

The ability to influence the reaction rate when driving a vehicle or working with other mechanisms

text

Precautionary measures

Undesirable side effects can be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms of the disease. If there is no improvement in symptoms, drug therapy should be discontinued. Elderly Patients Elderly patients have an increased incidence of adverse reactions to non-steroidal anti-inflammatory drugs, especially the incidence of gastrointestinal bleeding and perforation (even fatal in some cases), as well as impaired renal, hepatic and cardiac function. Therefore, appropriate clinical observation is recommended. Rare cases of serious liver reactions, including very rare cases of death, have been reported associated with the use of nimesulide-containing medicinal products. Patients who experience symptoms similar to those of liver damage during treatment with Nymefast (for example, anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine) or patients who have abnormal liver function laboratory tests should discontinue treatment with the drug. Repeated administration of nimesulide is contraindicated in such patients. Liver damage, most reversible, has been reported after short-term exposure to the drug. During treatment with Nymefast, the patient should refrain from taking long-term analgesics. The concomitant use of Nymefast and other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided. Patients receiving nimesulide who develop flu-like or cold-like symptoms should discontinue treatment with the drug. Gastrointestinal Disorders Gastrointestinal bleeding, ulceration, and perforation of an ulcer may be life-threatening if the patient's medical history contains records of similar problems occurring when taking any nonsteroidal anti-inflammatory drugs during treatment (regardless of the elapsed time), with the presence or without the presence of dangerous symptoms or a history of serious gastrointestinal disorders. The risk of gastrointestinal bleeding, ulceration, or perforation of an ulcer increases with increasing doses of nonsteroidal anti-inflammatory drugs, in patients with a history of ulcers, especially those complicated by hemorrhage or perforation, and in elderly patients. For these patients, treatment should be started with the lowest possible dose. For these patients, as well as patients taking concomitant low-dose aspirin or other drugs that increase the risk of gastrointestinal disease, combination therapy with protective agents (eg, misoprostol or proton pump inhibitors) should be considered. Patients with gastrointestinal toxicity, especially the elderly, should report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding). This is especially important in the initial stages of treatment. Gastrointestinal bleeding, as well as the formation of ulcers or perforations, are observed for all NSAIDs at different stages of treatment, regardless of the presence of warning symptoms or a history of gastrointestinal pathology. If gastrointestinal bleeding or ulceration develops, nimesulide should be discontinued. Nimesulide should be administered with caution to patients with gastrointestinal diseases, including peptic ulcers, a history of gastrointestinal bleeding, ulcerative colitis and Crohn's disease. Patients taking concomitant medications that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as aspirin, should be advised to use the drug with caution. If gastrointestinal bleeding or ulcers occur in patients receiving Nimefast, treatment with the drug should be discontinued. NSAIDs should be prescribed with caution to patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), since exacerbation of these diseases is possible. In patients with renal or heart failure, Nimefast should be used with caution as the drug may worsen renal function. If the condition worsens, treatment should be discontinued. Skin Reactions There have been reports of very rare cases of severe skin reactions to non-steroidal anti-inflammatory drugs, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, some of which can lead to death. Patients appear to be at greatest risk of developing skin reactions during the initial period of therapy. Nimefast should be discontinued at the first signs of skin rash, damage to the mucous membranes and other signs of hypersensitivity. Renal disorders Caution should be exercised when prescribing the drug to patients with impaired renal or cardiac function, since the use of nimesulide may lead to deterioration of renal function. If worsening occurs, treatment should be interrupted. Effect on fertility The use of nimesulide can reduce female fertility, so it is not recommended for women planning pregnancy. In women who have problems conceiving or are undergoing examination for infertility, discontinuation of nimesulide should be considered. Disorders of the cardiovascular and cerebrovascular system Patients with arterial hypertension and/or a history of mild/moderate acute heart failure, as well as patients with fluid retention and edema as a reaction to the use of NSAID therapy, require appropriate monitoring of their condition and consultation with a doctor. . Clinical studies and epidemiological data suggest that some nonsteroidal anti-inflammatory drugs, especially at high doses and when used for long periods of time, may lead to a small risk of arterial thrombotic events (eg, myocardial infarction or stroke). There is insufficient data to exclude the risk of such events when using nimesulide. In patients with uncontrolled hypertension, congestive heart failure, established coronary artery disease, peripheral arterial disease and/or cerebrovascular disease, nimesulide should be prescribed after careful evaluation. An equally thorough assessment of the condition should be performed before starting long-term treatment in patients with risk factors for cardiovascular disease (for example, arterial hypertension, hyperlipidemia, diabetes mellitus, smoking). Since nimesulide can affect platelet function, it should be prescribed with caution to patients with bleeding diathesis. However, Nimefast does not replace acetylsalicylic acid in the prevention of cardiovascular diseases. Effect on the ability to drive vehicles and operate machinery Patients who experience dizziness or drowsiness should refrain from driving a car or working with mechanisms that require increased concentration and precise coordination of movements when using Nymefast.

Interaction with other drugs

Pharmacodynamic interactions: Other non-steroidal anti-inflammatory drugs (NSAIDs) Concomitant use of drugs containing nimesulide and other non-steroidal anti-inflammatory drugs, including acetylsalicylic acid in anti-inflammatory doses (? 1 g once or ? 3 g as a total daily dose), is not recommended. Corticosteroids Increase the risk of gastrointestinal ulcers or bleeding. Anticoagulants NSAIDs may enhance the effect of anticoagulants such as warfarin or acetylsalicylic acid. Due to the increased risk of bleeding, this combination is not recommended and is contraindicated in patients with severe coagulation disorders. If combination therapy cannot be avoided, careful monitoring of blood clotting parameters is necessary. Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs) Increase the risk of gastrointestinal bleeding. Diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin type 2 receptor antagonists (AIIA) and NSAIDs may reduce the effectiveness of diuretics and other antihypertensive drugs. In some patients with impaired renal function (for example, in dehydrated or elderly patients), co-administration of ACE inhibitors or angiotensin II antagonists, as well as substances that inhibit the cyclooxygenase system, may cause a further decrease in renal function, including acute renal failure. which is usually reversible. This interaction should be taken into account in patients taking Nymefast together with ACE inhibitors or APAs. Therefore, caution should be exercised when prescribing this combination of drugs, especially in elderly patients. Patients should be kept adequately hydrated and the need to monitor renal function should be considered upon initiation of combination therapy and periodically thereafter. Pharmacokinetic interactions: effects of nimesulide on the pharmacokinetics of other drugs Furosemide In healthy volunteers, nimesulide temporarily reduced the effect of furosemide on sodium excretion, to a lesser extent on potassium excretion, and reduced the diuretic response. Co-administration of nimesulide and furosemide leads to a decrease (by approximately 20%) in the area under the concentration-time curve (AUC) and a decrease in the cumulative excretion of furosemide without changing the renal clearance of furosemide. Co-administration of furosemide and drugs containing nimesulide requires caution in patients with impaired renal or cardiac function. Lithium There is evidence that NSAIDs reduce the clearance of lithium, resulting in increased plasma lithium levels and lithium toxicity. When prescribing Nimefast to patients receiving lithium therapy, plasma lithium levels should be monitored frequently. In vivo studies were conducted to identify possible pharmacokinetic interactions with glibenclamide, theophylline, warfarin, digoxin, cimetidine and antacids (for example, a combination of aluminum and magnesium hydroxide). No clinically significant interactions were observed. Nimesulide inhibits the activity of the CYP2C9 enzyme. When taking drugs that are substrates of this enzyme with Nymefast, the concentration of these drugs in plasma may increase. When prescribing nimesulide less than 24 hours before or less than 24 hours after taking methotrexate, caution is required, since in such cases the plasma level of methotrexate and, accordingly, the toxic effects of this drug may increase. Due to their effect on renal prostaglandins, inhibitors of prostaglandin synthetase, such as nimesulide, may increase the nephrotoxicity of cyclosporines. Pharmacokinetic interactions: effects of other drugs on the pharmacokinetics of nimesulide In vitro studies have shown that nimesulide is displaced from binding sites by tolbutamide, salicylic acid and valproic acid. Although these interactions were determined in blood plasma, these effects were not observed during clinical use of the drug.

Contraindications

known hypersensitivity to nimesulide or to one of the excipients of the drug; hyperergic reactions that have occurred in the past (for example, bronchospasm, rhinitis, urticaria) in connection with taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs; past hepatoxic reactions to nimesulide; concomitant use of other substances with potential hepatotoxicity; alcoholism, drug addiction; previous gastrointestinal bleeding or perforation associated with previous NSAID therapy; gastric or duodenal ulcer in the acute phase, a history of ulcers, perforation or bleeding in the gastrointestinal tract; a history of cerebrovascular bleeding or other hemorrhages, as well as diseases accompanied by bleeding; severe blood clotting disorders; severe heart failure; severe renal failure; liver failure; patients with cold or flu symptoms; age up to 12 years; The use of the drug is contraindicated in the third trimester of pregnancy and during breastfeeding.

Compound

Each tablet contains: active substance: nimesulide 100 mg; excipients: microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate, povidone, lactose monohydrate.

Overdose

Symptoms of acute NSAID overdose are usually limited to the following: apathy, drowsiness, nausea, vomiting and epigastric pain. With maintenance therapy, these symptoms are usually reversible. Gastrointestinal bleeding may occur. In rare cases, increased blood pressure, acute renal failure, respiratory depression and coma may occur. Anaphylactoid reactions have been reported when taking therapeutic doses of NSAIDs and when overdosing such drugs. In case of NSAID overdose, treatment is symptomatic and supportive. There is no specific antidote. There is no data regarding the elimination of nimesulide by hemodialysis, however, based on the high level of binding to plasma proteins (up to 97.5%), it can be concluded that dialysis is ineffective in case of drug overdose. If there are symptoms of overdose or after taking a large dose of the drug, within 4 hours after administration, patients may be prescribed: inducing vomiting and/or taking activated charcoal (60-100 grams for adults) and/or taking an osmotic laxative. Forced diuresis, urine alkalinization, hemodialysis or hemoperfusion may be ineffective due to the high level of drug binding to blood proteins. Kidney and liver functions should be monitored.

Side effect

Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially in high doses and for long periods of time, may be associated with a slight increase in the risk of arterial thrombosis (eg, myocardial infarction or stroke). Edema, increased blood pressure and heart failure have also been reported during treatment with NSAIDs. With the use of NSAIDs, there is evidence of very rare cases of bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. When treated with NSAIDs, the most common adverse events were gastrointestinal events. Peptic ulcers, perforation or gastrointestinal bleeding may develop, sometimes with death, especially in elderly patients. There is information about the appearance of nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, tarry stools, vomiting blood, ulcerative stomatitis, exacerbation of colitis and Crohn's disease after taking the drug. Gastritis is less common. The side effects listed below are based on data obtained from controlled clinical studies* (approximately 7800 patients) and post-marketing studies. The frequency of cases is classified as follows: very common (? 1/10); often (? 1/100,

Storage conditions

Store in a place protected from light and moisture, at a temperature not exceeding 25 °C. Keep out of the reach of children.

How Nymefast interacts with other drugs

The simultaneous use of an anti-inflammatory drug and aspirin should not be allowed, as the likelihood of bleeding increases.

When the drug interacts with diuretics, the effect of the latter decreases, which means the excretion of sodium and potassium decreases. This is especially important for patients suffering from kidney and heart pathologies.

When taken simultaneously with drugs containing lithium, the toxicity of both drugs increases, and the level of lithium in the blood increases.

Taking Metatrexate and Nimefast may increase the toxic effects of Metatrexate, so monitoring is required.

Salicylic and valproic acid are able to displace nimesulide and prevent it from binding to plasma proteins, which may result in an increased amount of nimesulide in the plasma.

The combined use of anti-inflammatory drugs and clavulanic acid, antifungal agents and antibacterial agents is contraindicated, as toxic damage to the liver is possible.

The drug is stored in a cool, dark place, away from direct sunlight and children, at a temperature below 25°.

Nymefast took three tablets, what should I do?

Use in the Elderly Elderly patients are particularly susceptible to the side effects of NSAIDs, including gastrointestinal bleeding, renal, cardiac and hepatic dysfunction. Therefore, adequate clinical monitoring is recommended. ^ Special instructions The risk of side effects after using nimesulide can be reduced if treatment is carried out in a short course and the drug is discontinued upon achieving a therapeutic effect or due to ineffectiveness. Patients who experience deterioration in liver function during use of nimesulide (for example, anorexia, nausea, vomiting, abdominal pain, weakness, dark urine) or who experience abnormal liver function tests should discontinue use of the drug.

Such patients should not be re-prescribed nimesulide. There are known cases of liver damage even after short-term use of the drug.

However, nimesulide is not a replacement for acetylsalicylic acid for cardiovascular prevention. Nymefast contains lactose and is therefore not recommended for patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome.

It is recommended to avoid the combined use of Nymefast with alcoholic beverages. Effect on the ability to drive vehicles and operate machinery Patients who experience dizziness or drowsiness should refrain from driving a car or operating mechanisms that require increased concentration and precise coordination of movements when using Nimesulide-Rn.

Interaction with other drugs Pharmacodynamic interaction. Nymefast belongs to a new generation of NSAIDs, the mechanism of action of which is associated with selective inhibition of cyclooxygenase-2. Pharmacokinetics When taken orally, the drug is well absorbed from the gastrointestinal tract. The maximum concentration of the active substance in the blood plasma is achieved 2-3 hours after taking the drug. Taking the drug simultaneously with food slows down the rate of absorption, but does not affect the degree of absorption. Plasma protein binding is 97.5%. The volume of distribution is 0.19 – 0.35 l/kg. Nimesulide is actively metabolized in the liver with the formation of several metabolites, excreted mainly in urine (50%) and feces (29%). The main metabolite is the pharmacologically active hydroxynimesulide (25%). The half-life from plasma is 3.2 – 6 hours.

Are there any analogues of Nymefast?

The list is quite large. They all have the same active ingredient, but are produced by different manufacturing companies, which means they have different prices:

• Nimesulide;
• Actasulide;
• Aponil;
• Ameolin;
• Mesulide;
• Nise;
• Nimesil;
• Nimegesic;
• Nimulid;
• Novolid.

Nimesulide

Nise

Nimesil

Nimulid

Reviews

Sergey “I’ve been taking Nymefast for quite some time. At the same time, I suffer from joint pain, sometimes my legs ache unbearably and it is impossible to sleep, then I save myself with this drug. But since I’m already old, I’m afraid of complications and side effects on the stomach, so I take omeprazole at the same time as Nymefast. This combination also protects against joint pain and prevents stomach ulcers!”

Georgy “My friend decided to stop drinking, of course, not on his own, with the help of doctors, and so he began to experience withdrawal symptoms, to relieve which the doctors prescribed him Nymefast, since he had terribly strong headaches, he says it helps well. It turns out that you can drink it even after regular alcohol intoxication)"

Lyudmila “All my life I have suffered from pain during menstruation, when I was at school, I didn’t even go to classes, but now I work and no one gives me sick leave for this, so I have to save myself by various means. It has gotten to the point where neither no-spa, nor analgin, nor Tempalgin help anymore. The doctor advised - “Nimefast” is an excellent drug! And the main thing is that the pain goes away after 20 minutes and subsides for a long time, and that’s exactly what I need!”

What does Nymefast help with?

The use of nimesulide may impair female fertility and is not recommended for women planning pregnancy, having difficulty becoming pregnant, or undergoing examination for infertility. Like other NSAIDs that are known to inhibit prostaglandin synthesis, nimesulide can cause premature closure of the ductus arteriosus, pulmonary hypertension, oliguria, oligoamnion, increased risk of bleeding, weakness of labor and the development of peripheral edema. There have been isolated cases of renal failure in children of women taking nimesulide in late pregnancy. Use during lactation Passes into breast milk, therefore, its use during lactation is not recommended.